Systemic Retinoids and Advanced Care Options

When standard daily care—such as intensive bathing and heavy emollients—is not enough to manage the thick, plate-like scaling of Lamellar Ichthyosis (LI), specialists may consider systemic retinoids. These are powerful, vitamin A-derived medications taken by mouth that change how skin cells grow and shed ^[1][2].

Because these medications affect the entire body, they are generally reserved for more severe cases and require close, lifelong partnership with a dermatology team.

Common Oral Retinoids

Two primary oral retinoids are used for LI:

• Acitretin: Often considered a standard systemic choice for ARCI-spectrum disorders like LI. It is effective at thinning thick scales, but it stays in the body for a very long time ^[2][3].
• Isotretinoin: While more commonly known as a treatment for severe acne, isotretinoin is also used for ichthyosis. Both drugs are teratogenic, and the choice between them must follow current local labeling and specialist counseling ^[4][5].

Monitoring and Safety

Because systemic retinoids can affect internal organs and bone development, your child will need a baseline “check-up” followed by regular monitoring.

1. Laboratory Tests

Retinoids can influence how the liver processes fats and enzymes. Doctors typically monitor:

• Liver Enzymes: To ensure the medication is not causing inflammation in the liver ^[6][7].
• Lipids: Retinoids can raise triglycerides and cholesterol levels in the blood ^[6][8].

2. Bone and Growth Monitoring

One of the primary concerns with long-term retinoid use in children is the effect on the skeleton.

• Hyperostosis: This is a condition where extra bone grows along the spine or joints ^[9][10]. Routine laboratory monitoring is distinct from imaging; bone imaging or specialist evaluation should be individualized, not automatic, and you should report symptoms such as persistent bone or joint pain to your doctor.
• Growth Plates: There are rare reports of premature “closing” of the growth plates in the long bones, which could affect a child’s final height ^[11][12].
• Vitamin D: Some evidence suggests retinoids can impact Vitamin D levels. Supplementation should only be given at a clinician-recommended dose based on an individualized assessment of growth, symptoms, diet, and laboratory testing, because unnecessary vitamin-D treatment can also cause harm ^[13].

3. Physical Side Effects

Most patients experience mucocutaneous side effects—meaning effects on the skin and mucous membranes. These are dose-dependent and can include very dry lips (cheilitis), peeling skin on the palms and soles, and thinning hair ^[5][7].

Pregnancy and the ‘Three-Year Rule’

The most serious risk of systemic retinoids is teratogenicity, meaning they cause severe birth defects if a person becomes pregnant while taking them. Counseling should address reliable contraception, pregnancy testing as required locally, and breastfeeding.

• Acitretin Restriction: For people who can become pregnant, pregnancy must be avoided during treatment and for at least three years after stopping acitretin ^[14]. Furthermore, avoidance of alcohol is mandatory during treatment and for the period specified in the local product label because alcohol can promote the formation of etretinate, which stays in the body even longer.
• Isotretinoin Restriction: Isotretinoin also carries severe pregnancy risks, but the post-treatment restriction interval is much shorter. The choice and post-treatment interval must follow current local labeling and specialist counseling ^[5].

Investigational Therapies and Clinical Trials

Research is moving toward treatments that offer the benefits of retinoids without the systemic risks of a pill. However, these are experimental and not routine treatments.

• TMB-001 (Investigational Topical Isotretinoin): This is a specialized ointment currently being studied in clinical trials. In a Phase 2b study (CONTROL), a proportion of patients with LI reached a trial endpoint of a reduction in scaling ^[15]. While the amount of medication absorbed into the bloodstream was low, reduced systemic exposure does not by itself establish long-term safety or pregnancy safety ^[16]. It is investigational and unavailable outside appropriate access pathways.
• Targeted Therapies: Researchers are exploring other off-label options, such as dupilumab for severe itching associated with genetic skin disorders [NCT05649098] or topical lotions containing cholesterol and lovastatin (a therapy chiefly associated with particular disorders of cholesterol metabolism, not routine treatment for generalized LI) ^[17].

If you are interested in these advanced options, you can ask your doctor about participating in registries like the FARD cohort (a registry that helps researchers understand the long-term burden of rare skin diseases), ensuring you verify that enrollment information is current [NCT05954416].